<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03524352</url>
  </required_header>
  <id_info>
    <org_study_id>RC17_0021</org_study_id>
    <nct_id>NCT03524352</nct_id>
  </id_info>
  <brief_title>the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis</brief_title>
  <acronym>POCA</acronym>
  <official_title>Prospective Multicenter Randomized Controlled Double-blind Label Study of the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ulcerative colitis (UC) is a chronic inflammatory digestive (IBD) disease medically treated&#xD;
      with corticosteroids, aminosalicylates, immunomodulators, and biologics. Almost one third of&#xD;
      UC patients will require surgical interventions because of fulminant colitis, dysplasia,&#xD;
      cancer, or medical refractory diseases. Restorative proctocolectomy with ileal pouch-anal&#xD;
      anastomosis (IPAA) is the current standard surgical intervention. Anastomotic leak, pouch&#xD;
      failure, pelvic sepsis, and pouch ischemia can occur after the procedure, but the most common&#xD;
      long-term complication is pouchitis, an idiopathic inflammatory condition involving the ileal&#xD;
      reservoir. Symptoms of pouchitis are increased stool frequency, urgency, incontinence, bloody&#xD;
      stools, abdominal or pelvic discomfort, fatigue, malaise, and fever. The prevalence of&#xD;
      pouchitis ranges from 23 to 46 %, with an annual incidence up to 40 %. Though the majority of&#xD;
      initial cases of pouchitis are easily managed with a short course of antibiotics, in about 5&#xD;
      to 15 % of cases, inflammation of the pouch becomes chronic with very few treatments&#xD;
      available.&#xD;
&#xD;
      Fecal microbiota transplantation (FMT) is a novel therapy to transfer normal intestinal flora&#xD;
      from a healthy donor to a patient with a medical condition potentially caused by disrupted&#xD;
      homeostasis of intestinal microbiota or dysbiosis. FMT has been widely used in refractory&#xD;
      Clostridium difficile infection (CDI) and recently it has gained popularity for treatment of&#xD;
      inflammatory bowel disease (IBD). Previous studies suggested that manipulating the&#xD;
      composition of intestinal flora through antibiotics, probiotics, and prebiotic achieved&#xD;
      significant results for treating acute episodes of UC-associated pouchitis. However,&#xD;
      currently there is no established effective treatment for chronic antibiotic dependent&#xD;
      pouchitis. Our project aims to evaluate the delay of relapse in chronic recurrent pouchitis&#xD;
      after FMT versus sham transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days between the date of transplantation and the date of relapse according to physiological and endoscopic parameter (pochitis disease activity index)</measure>
    <time_frame>106 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of relapse rate according to physiological and endoscopic parameter (pochitis disease activity index)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapse rate according to pochitis disease activity index (physiological and endoscopic parameter)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days within the transplantation and the instauration of an antibiotherapy or alternative treatment</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of fecal microbiota engraftment by 16S sequencing</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)</measure>
    <time_frame>weeks -5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)</measure>
    <time_frame>0 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Pouchitis</condition>
  <arm_group>
    <arm_group_label>fecal microbiota</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fecal microbiota</intervention_name>
    <description>fecal microbiota in suspension</description>
    <arm_group_label>fecal microbiota</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>sterile saline</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ≥ 18 years at the time of signing the informed consent form (ICF).&#xD;
&#xD;
          -  Subject must understand and voluntarily sign an ICF prior to conduct the study related&#xD;
             assessments/procedure.&#xD;
&#xD;
          -  Willing and able to adhere to the study visit scheduled and other protocol&#xD;
             requirements.&#xD;
&#xD;
          -  Subjects must have been operated with ileal pouch anal anastomosis (IPAA) with a&#xD;
             duration of at least 6 month prior the screening visit.&#xD;
&#xD;
          -  Subject must have a diagnosis of recurrent pouchitis defined as at least 2 episodes in&#xD;
             the last year or relapsing immediately after a reasonable response to antibiotherapy.&#xD;
&#xD;
          -  Subject must be in remission with a Pouchitis Disease Activity Index (PDAI) &lt; 7 at the&#xD;
             screening&#xD;
&#xD;
          -  Subject must affiliation with social security system or beneficiary from such system&#xD;
&#xD;
          -  Female of childbearing potential must have a negative pregnancy test at screening and&#xD;
             must agree to practice effective methods of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Crohn disease or indeterminate colitis&#xD;
&#xD;
          -  Anastomotic stenosis&#xD;
&#xD;
          -  Subject with prior treatment by probiotic within 3 month prior to the transplantation&#xD;
             visit&#xD;
&#xD;
          -  Subject with prior treatment by corticosteroids within 6 weeks prior to the&#xD;
             transplantation visit&#xD;
&#xD;
          -  Subject with prior treatment by immunosuppressors within 3 month prior to the&#xD;
             transplantation visit&#xD;
&#xD;
          -  Prior treatment with a biologic within 3 month prior the transplantation visit&#xD;
&#xD;
          -  Documented active infection of any kind in the last 6 months&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt; 1.5 x 109 /L (1,500 mm3)&#xD;
&#xD;
          -  Infection with chronic HIV&#xD;
&#xD;
          -  Pregnant female or breastfeeding&#xD;
&#xD;
          -  Chronic medical or psychiatric disease that may interfere with subject's ability to&#xD;
             comply with study procedures&#xD;
&#xD;
          -  Administration of investigational drug within 3 months prior to planned FMT&#xD;
&#xD;
          -  Adults under guardianship, Safeguard justice or trusteeship&#xD;
&#xD;
          -  Subject with difficulty in follow-up (vacation, job transfer, geographical distance,&#xD;
             lack of motivation).&#xD;
&#xD;
          -  Patients with contraindication to colonoscopy or anesthesia (if necessary)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trang POISSON</last_name>
    <phone>+33 2 40 08 75 59</phone>
    <email>caroline.trang@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DIB</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BUISSON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Beaujon, Clichy</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BOUHNIK</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Henry Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>AMIOT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>PARIENTE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NANCEY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU of Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trang</last_name>
      <email>caroline.trang@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de l'Archet 2</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FILIPPI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sokol</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Sud- Hopital Haut-lévêque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LAHARIE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BOUGUEN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ALRIC</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>May 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent pouchitis</keyword>
  <keyword>fecal microbiota transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pouchitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

